Tolerance and Appetite Reduction of a Nutritional Solution With Intragastric Gelation Properties

Launched by SOCIÉTÉ DES PRODUITS NESTLÉ (SPN) · Aug 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a special type of drink that forms a gel-like substance in the stomach to see if it can help reduce appetite and support weight management. The idea is that this gel might make you feel fuller with fewer calories, which could help control how much you eat. The study will involve 24 adults who will try different versions of this drink and a control drink over several visits, to see how each affects their appetite.

To take part, you need to be between 18 and 65 years old, have a body weight slightly above what’s considered healthy (a BMI between 27 and 32), and have kept a stable weight over the last six months. Participants should be comfortable using devices like smartphones or laptops, as some study activities may involve technology. During the study, you’ll visit the research center four times, consume the test drinks, and complete some assessments about how full you feel. The study excludes people with certain health conditions, recent weight loss efforts, food allergies, or who are pregnant or breastfeeding. If you meet the requirements and want to help explore new ways to manage appetite and weight, this study might be a good fit.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or Female aged 18-65 years old (inclusive)
• • 2. Body Mass Index (BMI) 27 - 32kg/m2 (inclusive), measured and defined by the site
• • 3. Self-reported stable body weight for the past 6 months prior to screening (defined as not having gained or lost more than 5% of body weight)
• • 4. Comfortable using technology, such as a smartphone or laptop
• • 5. Willing and able to understand and sign a written informed consent prior to study entry
• • 6. Deemed able to comply with the requirements of the study protocol and consume study products by study nurse
• Exclusion Criteria:
• • 1. Currently or in the last 3 months, use of medications affecting weight, study outcomes, including fat absorption such as, but not limited to: GLP-1 receptor analogues, SGLT-2 inhibitors, weight loss medications, medications that affect gastric pH, and any of the following drugs: cephaloridine, verapamil, valproic acid, and sulfonylureas, usually acting by competitive inhibition of L-carnitine transport by OCTN2, Orlistat, antacids, proton pump inhibitors, antibiotics, steroids or medications affecting thyroid hormones or gut hormones, antipsychotic medications, or antidepressants. As reported by participant.
• • 2. Diagnosed with Eating behaviour disorders such as emotional or restrained eating determined or any ongoing psychiatric illness. As reported by participant.
• • 3. Currently or within the last 3 months or planning to during the course of the study being on a weight loss regime (defined by actively following a diet such as Atkins, weight watchers, meal replacements, low or very low carbohydrate diet, ketogenic diet, intermediate fasting or enrolled into a governmental health program) or applying significant restrictions on food intake (i.e., regular breakfast skipping, regular cut on carbohydrates, regular intermittent fasting, diet reducing a specific macronutrient, diet significantly reducing calorie intake, excluding a group of food that was not excluded before). As reported by participant.
• • 4. Any known/suspected food allergies. As reported by participant.
• • 5. Currently pregnant, lactating, or breastfeeding. As reported by participant.
• • 6. Unstable diagnosed chronic conditions (such as hypertension, cardiovascular diseases, liver diseases, renal diseases, metabolic diseases). Unstable is defined as a change in medications in the past 3 months, or a change in disease severity in the past 3 months. As reported by participant.
• • 7. Acute GI upset (such as diarrhoea/constipation in the last 2 weeks, abdominal cramping etc.). As reported by participant.
• • 8. Diagnosed with chronic GI disorder such as inflammatory bowel disease, Crohn's disease, ulcerative colitis, or irritable bowel syndrome. As reported by participant.
• • 9. Ever underwent surgery for weight loss such as bariatric procedures or gastric bypass. As reported by participant.
• • 10. Recent blood donation (\<8 weeks). As reported by participant.
• • 11. Current or past smokers (stopped less than 3 months ago). As reported by participant.
• • 12. Any drug abuse within the past year. As reported by participant.
• • 13. Alcohol consumption above levels recommended for healthy adults: Average alcohol intake \> 2 standard drinks per day over a week for males or \> 1 standard drink per day over a week for females as reported by the participant. One standard drink contains 10-12 g of ethanol, i.e., 0.3 dl of strong alcohols, 1dl of wine, 3 dl of beer. As reported by participant.
• • 14. Currently participating in another interventional study. As reported by participant.
• • 15. Family or hierarchical relationships with the research team members. As reported by participant.